FDA Accepts Application for Merck's KEYTRUDA® as Adjuvant Therapy for Stage IB -IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection Life Science Investing
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab in Patients with Relapsed/Refractory Large B-cell Lymphoma at the European Hematology Association Annual Congress Pharmaceutical Investing
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients Pharmaceutical Investing
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment Pharmaceutical Investing
Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
